Every week, I send out an email with observations about markets, investments, and random other subjects. These emails will help you shape your world view, they will teach you new investment strategies, and they will also give you new ideas that you can research further.

MOST POPULAR WEEKLY DISPATCHES

Concentrated bets – how the world's best value investors got rich

How I work (part 2): The 10 worst mistakes of my investing career

The value of going against groupthink

Riches among ruins (part 2): my 5,000% investment adventure in war-torn Iraq

Ferrari – the company, the stock, and my car

11 highlights from our dinner with Kuppy

Sark – bidding for the Barclay estate and going public

USA – the unstoppable juggernaut?

Hungary investor trip – what we learned

"The art of execution": how to manage your own portfolio

The Economist: a good investment?

It’s little-known, but The Economist has over 1,000 shareholders. It’s akin to an exclusive club, which rather wants to keep you out. Will you be able to buy stock regardless – and could a proper IPO beckon?

read more

Subscribe to my news

  • Get your weekly dose of investment inspiration - and my FREE eBook "Weird Shit Investing 2024 - The Manual".
  • You can unsubscribe at any time. I'll treat your data with respect, see my Privacy Policy for details.
  • This field is for validation purposes and should be left unchanged.

Archive

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.